UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
European journal of cancer (1990), ISSN 0959-8049, 09/2002, Volume 38, Issue 14, pp. 1814 - 1814
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2017, Volume 389, Issue 10075, pp. 1195 - 1205
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antineoplastic Agents, Immunological - administration & dosage | Trastuzumab - therapeutic use | Drug Administration Schedule | Follow-Up Studies | Biomarkers, Tumor - analysis | Humans | Middle Aged | Kaplan-Meier Estimate | Trastuzumab - adverse effects | Treatment Outcome | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Antineoplastic Agents, Immunological - adverse effects | Breast Neoplasms - chemistry | Antineoplastic Agents, Immunological - therapeutic use | Breast Neoplasms - pathology | Chemotherapy, Adjuvant - methods | Adult | Female | Aged | Receptor, ErbB-2 - analysis | Heart Diseases - chemically induced | Antimitotic agents | Medical colleges | Analysis | Adjuvant treatment | Monoclonal antibodies | Breast cancer | Antineoplastic agents | Cancer | Heart | Medical research | Laboratories | Toxicity | Health risks | Clinical trials | Mammography | Radiation therapy | Cancer therapies | Patients | Survival | ErbB-2 protein | Incidence | Chemotherapy | Motivation | Failure analysis | Surgery | Informed consent | Heart diseases | Trastuzumab | Schedules | Clinical outcomes | Index Medicus | Abridged Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 06/2018, Volume 19, Issue 6, pp. 737 - 746
Journal Article
The lancet oncology, ISSN 1470-2045, 2011, Volume 12, Issue 3, pp. 236 - 244
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Combined Modality Therapy | Breast Neoplasms - drug therapy | Breast Neoplasms - metabolism | Randomized Controlled Trials as Topic | Breast Neoplasms - therapy | Antibodies, Monoclonal, Humanized | Breast Neoplasms - pathology | Survival Analysis | Adult | Female | Receptor, ErbB-2 | Chemotherapy, Adjuvant | Trastuzumab | Antimitotic agents | Care and treatment | Epidermal growth factor | Adjuvant treatment | Cameron, David (British prime minister) | Breast cancer | Antineoplastic agents | Cancer | Index Medicus
Journal Article
Breast (Edinburgh), ISSN 0960-9776, 08/2013, Volume 22, Issue 2, pp. S3 - S7
Primary Breast Cancer | St. Gallen Breast Cancer Consensus | Breast Cancer: Optimal Primary Therapy | Breast Cancer Treatment Guidelines | Oncology | Life Sciences & Biomedicine | Obstetrics & Gynecology | Science & Technology | Breast Neoplasms - surgery | Triazoles - adverse effects | Prognosis | Humans | Middle Aged | Mastectomy - methods | Neoplasm Recurrence, Local - mortality | Neoplasm Recurrence, Local - pathology | Antineoplastic Agents, Hormonal - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Postmenopause | Adult | Female | Chemotherapy, Adjuvant | Triazoles - therapeutic use | Premenopause | Risk Assessment | Neoplasm Recurrence, Local - therapy | Awards and Prizes | Treatment Outcome | Breast Neoplasms - drug therapy | Consensus Development Conferences as Topic | Switzerland | Randomized Controlled Trials as Topic | Disease-Free Survival | Breast Neoplasms - genetics | Tamoxifen - therapeutic use | Genes, erbB-2 - genetics | Survival Analysis | Breast Neoplasms - mortality | Aged | Tamoxifen - adverse effects | Nitriles - adverse effects | Precision Medicine - methods | Nitriles - therapeutic use | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 03/2020, Volume 21, Issue 3, pp. e130 - e130
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 2, pp. 131 - 132
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 848 - 858
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Follow-Up Studies | Humans | Middle Aged | Dose-Response Relationship, Drug | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Invasiveness - pathology | Antineoplastic Agents, Hormonal - therapeutic use | Adult | Female | Ovary - drug effects | Chemotherapy, Adjuvant | Drug Administration Schedule | Risk Assessment | Administration, Oral | Early Detection of Cancer | Self Report | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - pathology | Tamoxifen - therapeutic use | Premenopause - physiology | Survival Analysis | Quality of Life | Breast Neoplasms - mortality | Tamoxifen - adverse effects | Neoplasm Staging | Index Medicus
Journal Article
Breast (Edinburgh), ISSN 0960-9776, 2013, Volume 22, pp. S3 - S7
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 09/2013, Volume 31, Issue 25, pp. 3083 - 3090
Life Sciences & Biomedicine | Oncology | Science & Technology | Gynecology. Andrology. Obstetrics | Mammary gland diseases | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Tumors | Breast Neoplasms - classification | Humans | Middle Aged | Treatment Outcome | Lymphatic Metastasis | Receptors, Estrogen - analysis | Incidence | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Breast Neoplasms - pathology | Adult | Breast Neoplasms - mortality | Female | Aged | Neoplasm Recurrence, Local - epidemiology | Receptor, ErbB-2 - analysis | Index Medicus | Bc5 | ORIGINAL REPORTS | Bc7
Journal Article
The New England journal of medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 5, pp. 436 - 446
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Breast Neoplasms - surgery | Premenopause | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - drug therapy | Antineoplastic Agents, Hormonal - adverse effects | Disease-Free Survival | Aromatase Inhibitors - adverse effects | Breast Neoplasms - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Tamoxifen - therapeutic use | Mastectomy | Adult | Female | Androstadienes - therapeutic use | Chemotherapy, Adjuvant | Tamoxifen - adverse effects | Androstadienes - adverse effects | Aromatase Inhibitors - therapeutic use | Chemotherapy | Womens health | Invasiveness | Estrogens | Population studies | Breast cancer | Reproductive system | Tamoxifen | Drug therapy | Survival | Patients | Statistical analysis | Endocrine therapy | Radiation therapy | Cancer therapies | Survival analysis | Health risk assessment | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 07/2014, Volume 371, Issue 2, pp. 107 - 118
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Gynecology. Andrology. Obstetrics | Mammary gland diseases | General aspects | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Tumors | Estradiol - blood | Breast Neoplasms - surgery | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Mastectomy | Adult | Female | Chemotherapy, Adjuvant | Aromatase Inhibitors - therapeutic use | Osteoporosis - chemically induced | Premenopause | Kaplan-Meier Estimate | Triptorelin Pamoate - adverse effects | Triptorelin Pamoate - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tamoxifen - therapeutic use | Quality of Life | Androstadienes - therapeutic use | Tamoxifen - adverse effects | Androstadienes - adverse effects | Care and treatment | Breast cancer | Research | Ovariectomy | Invasiveness | Estrogens | Radiation | Clinical trials | Data processing | Pituitary (anterior) | Gonadotropins | Tamoxifen | Survival | Patients | Clinical outcomes | Post-menopause | Chemotherapy | Aromatase | Index Medicus | Abridged Index Medicus
Journal Article